SOURCE: ImmuneRegen BioSciences

ImmuneRegen BioSciences

April 19, 2010 13:00 ET

ImmuneRegen BioSciences® Retains Redwood Consultants, LLC to Assist in Shareholder Relations and Strategic Planning

SCOTTSDALE, AZ--(Marketwire - April 19, 2010) - ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTCBB: IRBS), is pleased to announce today that the Company has retained California-based Redwood Consultants, LLC to assist in shareholder relations and investor communications.

ImmuneRegen CEO Michael Wilhelm said, "We are very pleased to commence and announce our relationship with Redwood Consultants and are committed to providing timely and consistent updates to the investment community. We will be working closely with senior management of Redwood to keep the global investment community apprised of our progress at all levels."

About Redwood Consultants, LLC

Redwood Consultants, LLC is a full-service investor relations firm that works closely with emerging, publicly traded companies to communicate their value to the investment community and build and sustain greater investor sponsorship. Committed to their clients' success, Redwood's mission is to deliver highly credible information and comprehensive research on the corporate potential of the emerging companies they represent to the Wall Street community of analysts, institutional investors and retail stockbrokers. Redwood Consultants recognizes that small, innovative companies must align themselves with a trusted investor relations partner to successfully compete in today's new-market environment. Redwood is known throughout the financial community for their loyalty, integrity and credibility. For more information, see www.redwoodconsultants.com.

About ImmuneRegen BioSciences, Inc.

ImmuneRegen BioSciences Inc., a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTCBB: IRBS), is a development-stage biotechnology company focused on the research, development and licensing of Homspera® and its derivatives. Homspera is an adult stem cell active compound that in study results has been shown to regenerate and strengthen the immune system and enhance wound healing. Additional intended uses being developed include influenza as a stand-alone or combination therapy and as a vaccine adjuvant. To advance its mission, the Scottsdale, Arizona based company has forged numerous study partnerships with industry and academic leaders, including Celgene Cellular Therapeutics, HemoGenix, Lovelace Respiratory Research Institute and Virion Systems. For more information, please visit www.immuneregen.com.

Forward-Looking Statements:

Statements about the Company's future expectations, including statements about the potential use and scientific results for the Company's drug candidates, science and technology, and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. These future events may not occur as and when expected, if at all, and, together with the Company's business, are subject to various risks and uncertainties. The Company's actual results could differ materially from expected results as a result of a number of factors, including the uncertainties inherent in research and development collaborations, pre-clinical and clinical trials and product development programs (including, but not limited to the fact that future results or research and development efforts may prove less encouraging than current results or cause side effects not observed in current pre-clinical trials), the evaluation of potential opportunities, the level of corporate expenditures and monies available for further studies, capital market conditions, and others set forth in the Company's periodic report on Form 10-Q for the three months ended September 30, 2009 as filed with the Securities and Exchange Commission and report on Form 10-K for the year ended December 31, 2008 as filed with the Securities and Exchange Commission. There are no guarantees that any of the Company's proposed products will prove to be commercially successful. The Company undertakes no duty to update forward-looking statements.

Contact Information

  • Contact:
    Michael K. Wilhelm OR John Fermanis
    ImmuneRegen BioSciences Inc.
    Phone: 480-922-3926
    Email: Email Contact
    Email: Email Contact

    Investor Contact:
    Redwood Consultants, LLC at 415-884-0348